The market is a bit quiet and nervous these days, even with some strong results from some companies. Although Thermo Fisher ( TMO ) guidance was not overly impressive in this earnings season, the quality of the business is there and willI’m a Portfolio manager (flexible equity funds and private clients), fundamental equity research, macro and geopolitical strategy.Over 10 years across global markets, managing multi-asset strategies and equity portfolios at a European asset manager.I combine top-down macro, ...

Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported fourth-quarter 2025 adjusted earnings of $6.57 per share, beating the street view of $6.45.Quarterly sales of $12.22 billion increased 7% year-over-year, beating the analyst consensus estimate of $11.95 billion. Organic revenue growth was 3%.“Throughout the year, we effectively navigated the external environment and leveraged our PPI Business System to enable excellent operational performance. It was also a very active year for capital deployment ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - The company reported strong financial performance for 2025, with revenue growth of 4% to $44.56 billion and adjusted EPS growth of 5% to $22.87 per share, reflecting effective management and operational excellence [5][22][30] - The company is well-positioned for 2026, initiating revenue guidance of $46.3 billion to $47.2 billion, representing 4% to 6% growth, and adjusted EPS guidance of $24.22 to $24.80, indicating 6% to 8% growth [22][40][43] Financial Performance - Q4 revenue grew 7% year over year to $12.21 billion, with adjusted operating income increasing 6% to $2.88 billion and adjusted EPS rising 8% to $6.57 per share [5][27] - For the full year, adjusted operating margin was 22.7%, with total adjusted operating income of $10.11 billion [5][29] - The company experienced a 3% organic growth in Q4, with a 2% contribution from acquisitions and a 2% tailwind from foreign exchange [28][30] Market Performance - In the pharma and biotech sector, Q4 growth was high single digits, driven by strong performance in bioproduction and research channels, while full-year growth was mid-single digits [6][8] - The academic and government market saw low single-digit declines, impacted by macro conditions in the US and China [7] - Diagnostics and healthcare delivered low single-digit growth in Q4, with flat growth for the full year [8] Growth Strategy - The company's growth strategy is based on three pillars: high-impact innovation, trusted partner status with customers, and a strong commercial engine [8][12] - Significant innovations in 2025 included the launch of high-impact products in chromatography, mass spectrometry, and bioproduction, enhancing the company's competitive position [9][10][11] Capital Deployment - In 2025, the company deployed approximately $16.5 billion, including $13 billion for mergers and acquisitions and $3.6 billion returned to shareholders through stock buybacks and dividends [15][34] - Key acquisitions included the filtration and separation business from Solventa and a sterile fill-finish site from Sanofi, enhancing the company's capabilities [16][34] Operational Excellence - The PPI business system played a critical role in managing costs and driving operational excellence, contributing to strong earnings growth [19][30] - The company plans to integrate artificial intelligence into its PPI system to further enhance operational efficiency [19] Corporate Social Responsibility - The company increased the use of renewable energy and expanded zero waste certification across its operations, aligning with long-term sustainability commitments [20] - Efforts to expand access to STEM and advance global health equity were highlighted as part of the company's mission-driven culture [20]

Key Takeaways TMO reported Q4 adjusted EPS of $6.57, up 7.7% year over year, while revenues rose 7.1% to $12.22B. TMO saw strength in Life Sciences and Laboratory Products offsetting slower growth in Analytical Instruments. TMO posted margin contraction as costs rose, even as cash and short-term investments jumped to $10.11B. Thermo Fisher Scientific Inc.'s (TMO) fourth-quarter 2025 adjusted earnings per share (EPS) of $6.57 beat the Zacks Consensus Estimate by 2.1%. The figure increased 7.7% year over year ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsCasey Woodring - VP of Life Science Tools and Diagnostics Equity ResearchDan Arias - Managing Director of Life Science and DiagnosticsMarc Casper - Chairman, President and CEOMichael Ryskin - Managing Director in Healthcare Equity ResearchRafael Tejada - VP of Investor RelationsStephen Williamson - SVP and CFOConference Call ParticipantsDan Brennan - Life Science and Diagnostic Tools Research AnalystJa ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Company ParticipantsCasey Woodring - VP of Life Science Tools and Diagnostics Equity ResearchDan Arias - Managing Director of Life Science and DiagnosticsMarc Casper - Chairman, President and CEOMichael Ryskin - Managing Director in Healthcare Equity ResearchRafael Tejada - VP of Investor RelationsStephen Williamson - SVP and CFOConference Call ParticipantsDan Brennan - Life Science and Diagnostic Tools Research AnalystJa ...

Thermo Fisher Scientific (NYSE:TMO) Q4 2025 Earnings call January 29, 2026 08:30 AM ET Speaker7Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 fourth quarter conference call. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad. I would now like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President, Investor R ...

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.13%. A quarter ago, it was expected that this maker of scientific instrument and laboratory supplies would post earnings of $5.5 per share when it actually produced earnings of $5.79, delivering a surpris ...

Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on strong demand for its tools and services used in drug development by pharmaceutical clients. ...